Therapeutic Asset Ratings

251 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Iparomilimab Triple-Negative Breast Cancer (TNBC)	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2/3	CCC (55)
Tuvonralimab Triple-Negative Breast Cancer (TNBC)	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2/3	CCC (55)
Pyrotinib Radiotherapy	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (54)
rc48-adc Radiotherapy	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (54)
Romiplostim Hematologic Malignancies	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (54)
Tislelizumab Radiotherapy	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (54)
Adebrelimab Brain Metastasis From Advanced HER2-negative Breast Cancer	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Adebrelimab HER2-Negative Locally Advanced Breast Cancer	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Aitua Combination Antibody Fallopian Tube Cancers	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Aitua Combination Antibody High-grade Serous Ovarian Cancer (HGSOC)	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Al18F-PSMA-BCH Malignancy	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Capecitabine Adolescents	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Capecitabine Cadonilimab	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Capecitabine Children	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Capecitabine Drug Use	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Capecitabine First-Line	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Capecitabine Nanoliposomal Irinotecan	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Capecitabine Oxaliplatin	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Capecitabine RAS-mutated	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Capecitabine Tislelizumab	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Carboplatin MSS	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Catequentinib Adolescents	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Catequentinib Children	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Catequentinib Whole Brain Radiotherapy	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Cyclophosphamide Pembrolizumab	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)

Showing 51 to 75 of 251 assets

PreviousPage 3 of 11Next